The growing use of GLP-1 obesity and diabetes drugs is linked to an estimated fall of more than one billion pounds a year in British grocery spending, consumer data firm Worldpanel by Numerator said on Thursday.
British households with at least one GLP-1 user spend on average 389 pounds less on groceries in the first year after treatment begins than would be expected based on comparable households, the research found.
Across the market, the estimated fall now exceeds one billion pounds a year, up from a previous estimate of 780 million pounds. That amounts to around 415 million fewer packs sold.
The research is based on data from 9,629 British households and compares the shopping of those using the drugs with households that do not. The figures are a statistical estimate of the effect on purchases, not a record of money saved by each user, and the comparison does not prove that every change in behaviour is due to the medication alone.
Use rising fast
In February 2026, 6.3 per cent of British households included at least one person taking GLP-1 drugs. By August, that had risen to 8.5 per cent. About 2.6 million adults in Britain were using the treatments during the period of the research, the company said.
The number of men using the drugs is estimated to have almost doubled in six months, from 440,000 in February to 830,000 in August. Men now make up 32 per cent of users, compared with 23 per cent at the start of the period.
The availability of the drugs in tablet form in Britain appears to be making them easier to access for some patients who do not want injections. Worldpanel expects the share of British households with at least one GLP-1 user to exceed 10 per cent during 2027.
Products gaining and losing
The biggest pressure is on impulse purchases. Spending on alcohol and crisps fell further in households with GLP-1 users than in those without, with the gap reaching around 15 per cent.
Some categories are gaining. Among users, purchases of frozen ready meals rose by 30 per cent in volume, which the researchers link to a preference for convenience and controlled portions. Spending on hot chocolate and malted drinks rose by 22 per cent.
Spending moves elsewhere
Households with GLP-1 users spent a total of 78 million pounds more than expected on health and personal care products in the first year of use. Thirty per cent of users said they had increased their spending on clothing and footwear.
The data does not show exactly how much of the money not spent on food goes to other markets.
GLP-1 drugs mimic hormones involved in regulating appetite and blood sugar. Some are used to treat type 2 diabetes, while others are approved for weight management under specific conditions. Their growing use has created a large and fast-growing pharmaceutical market, and the world’s biggest drugmakers have been in a multi-billion-dollar race to bring their own anti-obesity treatments to market.
(With information from Reuters and The Grocer)




